Mostrar el registro sencillo del ítem

dc.creatorSakkas, L. I.en
dc.creatorChikanza, I. C.en
dc.creatorPlatsoucas, C. D.en
dc.date.accessioned2015-11-23T10:46:49Z
dc.date.available2015-11-23T10:46:49Z
dc.date.issued2012
dc.identifier10.2174/157339712801318920
dc.identifier.issn15733971
dc.identifier.urihttp://hdl.handle.net/11615/32795
dc.description.abstractSystemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur very early in the disease process, and inflammatory infiltrates in the skin are restricted in early-phase disease. There is good evidence that fibroblast activation with collagen production may be triggered by the immune system. In early-phase disease, we slowly move from general immunosuppression to therapeutically targeting specific molecules involved in immune activation, such as T cell-directed targets, B cell-directed targets, cytokine targets, and tyrosine kinases targets. © 2012 Bentham Science Publishers.en
dc.source.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-84870179518&partnerID=40&md5=bcd174e3b20dbc84d05411647384e87a
dc.subjectB cellen
dc.subjectFibroblasten
dc.subjectImmune activationen
dc.subjectImmunotherapyen
dc.subjectSystemic sclerosisen
dc.subjectT cellen
dc.subjectTargeted therapyen
dc.subjectabatacepten
dc.subjectautoantibodyen
dc.subjectbasiliximaben
dc.subjectbelimumaben
dc.subjectbleomycinen
dc.subjectbosentanen
dc.subjectCD20 antibodyen
dc.subjectcollagenen
dc.subjectcollagen type 1en
dc.subjectcyclophosphamideen
dc.subjectcyclosporin Aen
dc.subjectcytokineen
dc.subjectdipeptidyl carboxypeptidase inhibitoren
dc.subjectendothelin receptor antagonisten
dc.subjecteverolimusen
dc.subjecthalofuginoneen
dc.subjectimatiniben
dc.subjectimmunoglobulinen
dc.subjectmethotrexateen
dc.subjectmonoclonal antibodyen
dc.subjectmonoclonal antibody IL13en
dc.subjectmonoclonal antibody TGFbeta1en
dc.subjectmycophenolic acid 2 morpholinoethyl esteren
dc.subjectprotein tyrosine kinaseen
dc.subjectrapamycinen
dc.subjectrecombinant gamma interferonen
dc.subjectrituximaben
dc.subjectthymocyte antibodyen
dc.subjecttocilizumaben
dc.subjectunclassified drugen
dc.subjectunindexed drugen
dc.subjectalopeciaen
dc.subjectantibody productionen
dc.subjectarticleen
dc.subjectautologous hematopoietic stem cell transplantationen
dc.subjectB lymphocyteen
dc.subjectchronic graft versus host diseaseen
dc.subjectchronic myeloid leukemiaen
dc.subjectdiarrheaen
dc.subjectdisease courseen
dc.subjectdrug mechanismen
dc.subjectdrug megadoseen
dc.subjectdrug targetingen
dc.subjectfatigueen
dc.subjectfinger ulceren
dc.subjectfluid retentionen
dc.subjectgastrointestinal tumoren
dc.subjectgraft versus host reactionen
dc.subjecthumanen
dc.subjecthumoral immune deficiencyen
dc.subjecthypertriglyceridemiaen
dc.subjectimmune systemen
dc.subjectimmunopathogenesisen
dc.subjectimmunosuppressive treatmenten
dc.subjectinflammatory infiltrateen
dc.subjectinterstitial lung diseaseen
dc.subjectlung fibrosisen
dc.subjectlung functionen
dc.subjectmicroangiopathyen
dc.subjectmyalgiaen
dc.subjectnonhumanen
dc.subjectnonmyeloablative stem cell transplantationen
dc.subjectpriority journalen
dc.subjectpulmonary hypertensionen
dc.subjectsclerodermaen
dc.subjectside effecten
dc.subjectskinen
dc.subjectskin examinationen
dc.subjectsystemic lupus erythematosusen
dc.subjectT lymphocyteen
dc.subjectunspecified side effecten
dc.subjectwhole body radiationen
dc.titleSystemic sclerosis: From pathogenesis towards targeted immunotherapiesen
dc.typejournalArticleen


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem